Literature DB >> 44374

Relationship of butaperazine blood levels to plasma prolactin in chronic schizophrenic patients.

R C Smith, C A Tamminga, J W Crayton, H Dekirmenjian, J M Davis.   

Abstract

The relationship of plasma prolactin to plasma or red blood cell butaperazine levels was investigated in chronic schizophrenic patients treated with clinical doses of butaperazine, both after a single acute dose of the drug and during regular, twice daily butaperazine administration. Although there was a significant curvilinear relationship between peak plasma butaperazine levels after an acute single oral dose of butaperazine and the maximum prolactin response that we measured, steady-state levels of plasma or red cell butaperazine and plasma prolactin were not related. We conclude that plasma prolactin cannot be used as a substitute for or even as a rough indicator of butaperazine blood levels in chronic schizophrenic patients being treated with clinical doses of butaperazine.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 44374     DOI: 10.1007/bf00431985

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  16 in total

1.  Human prolactin responses to neuroleptic drugs correlate with antischizophrenic potency.

Authors:  G Langer; E J Sachar; P H Gruen; F S Halpern
Journal:  Nature       Date:  1977-04-14       Impact factor: 49.962

Review 2.  Neuropharmacologic control of neuroendocrine function in man.

Authors:  L A Frohman; M E Stachura
Journal:  Metabolism       Date:  1975-02       Impact factor: 8.694

3.  Correlation between plasma levels of prolactin and chlorpromazine in psychiatric patients.

Authors:  T Kolakowska; D H Wiles; A S McNeilly; M G Gelder
Journal:  Psychol Med       Date:  1975-05       Impact factor: 7.723

4.  Plasma butaperazine levels in long-term chronic non-responding schizophrenics.

Authors:  R C Smith; H Dekirmenjian; J M Davis; J Crayton; H Evans
Journal:  Commun Psychopharmacol       Date:  1977

5.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

Authors:  I Creese; D R Burt; S H Snyder
Journal:  Science       Date:  1976-04-30       Impact factor: 47.728

6.  Pharmacokinetics of red blood cell phenothiazine and clinical effects. Acute dystonic reactions.

Authors:  D L Garver; J M Davis; H Dekirmenjian; F D Jones; R Casper; J Haraszti
Journal:  Arch Gen Psychiatry       Date:  1976-07

7.  Prolactin responses to neuroleptics in normal and schizophrenic subjects.

Authors:  P H Gruen; E J Sachar; G Langer; N Altman; M Leifer; A Frantz; F S Halpern
Journal:  Arch Gen Psychiatry       Date:  1978-01

8.  Determination of butaperazine in plasma and red blood cells by fluorometry.

Authors:  H Dekirmenjian; J I Javaid; U Liskevych; J M Davis
Journal:  Anal Biochem       Date:  1980-06       Impact factor: 3.365

9.  The pharmacokinetics of butaperazine in serum.

Authors:  J M Davis; D S Janowsky; H J Sekerke; H Manier; M K el-Yousef
Journal:  Adv Biochem Psychopharmacol       Date:  1974

10.  The effect of neuroleptics on serum prolactin in schizophrenic patients.

Authors:  H Y Meltzer; V S Fang
Journal:  Arch Gen Psychiatry       Date:  1976-03
View more
  1 in total

1.  A preliminary study of sex-related differences in prolactin responses to dopamine blockade and insulin hypoglycemia and in penfluridol plasma levels in schizophrenic patients.

Authors:  R S Nathan; E J Sachar; L Ostrow; G M Asnis; U Halbreich; F Halpern; N L Renzi; V Slotnick
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.